The Utilisation of a New Strength Citrate Anticoagulant during Centrifugal Plateletpheresis

Publisher Website
Google Scholar
Abstract
Employing the Hemonetics Blood Processor (IFC), a relatively pure platelet concentrate could be prepared by collecting only the 1st portion of the PRP [platelet-rich plasma] leaving the centrifuge bowl (Fraction I). A subsequent fraction containing RBC [red blood cells] and WBC [white blood cells] contaminants could be purified by a 2nd centrifugation, using a conventional blood bank centrifuge (Fraction II), if transfusion of these contaminants would be detrimental to the recipient. Utilizing the new 1.4% Na3-citrate anticoagulant, platelet metabolic parameters (ATP, ADP, AMP, lactate and pyruvate) and O2-uptake, were determined in Fractions I and II prepared from 10 normal healthy subjects. In contrast to previous studies reporting marked dysfunction in platelets contained in Fraction II when standard ACD-A [acid-citrate-dextrose used as an anticoagulant] was used during IFC, no significant difference (Student''s t test) was observed in the present study between Fractions I and II, in regard to platelet metabolism, when using the new anticoagulant. The 2nd centrifugal manipulation does not exert a detrimental effect on platelet metabolism.